Drugs / TP-38
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00074334 | May 2004 → Jun 2006 | central nervous system neoplasm | Pediatric Brain Tumor Consortium | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00104091 | Dec 2004 → Apr 2007 | glioblastoma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00071539 | Oct 2003 → Jan 2006 | glioblastoma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP-38 | “A Phase I/II Study Of A Recombinant Chimeric Protein Composed Of Transforming Growth Factor (TGF)-a And A Mutated Pseudomonas Exotoxin Termed PE38 (TP-38)” NCT00074334 ↗ |
| Known as | TGFa-PE38 toxin | “Patients receive TGFa-PE38 toxin (TP-38) intratumorally through 2 or 3 catheters” NCT00074334 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant chimeric protein” NCT00071539 ↗ |
| Route | Other | “Patients receive TGFa-PE38 toxin (TP-38) intratumorally through 2 or 3 catheters” NCT00074334 ↗ |